GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for BAV

BAV

Official Title

Beta Blockers and Angiotensin Receptor Blockers in Bicuspid Aortic Valve Disease Aortopathy (BAV Study)

Status

Ongoing

Overview

To evaluate the efficacy of beta blockers and angiotensin receptor blockers in the prevention of aortic dilatation and associated complications in adults with bicuspid aortic valve (BAV) disease.

Study Design

Randomized, double-blind, prospective, multicentre, placebo-controlled, two-arm trial of adult patients with bicuspid aortic valve aortopathy.

Primary Endpoint

The primary outcome is the change from baseline in the ascending aorta size, which will be evaluated by MRI scanning. Secondary outcome is rate of change in ascending aorta size using transthoracic echocardiography.

Number of Patients

416

Number of Sites

12

Number of Countries

1

Study Period

2010–2017

Principal Investigator

Judith Therrien

Program Manager

Tara McCready

Research Coordinator

Tara McCready

Collaborators

Investigators on behalf of the Canadian Adult Congenital Heart (CACH) Disease Network